Welcome to our dedicated page for Synlogic news (Ticker: SYBX), a resource for investors and traders seeking the latest updates and insights on Synlogic stock.
Synlogic, Inc. (SYBX) pioneers synthetic biology solutions targeting rare metabolic disorders through its innovative engineered probiotics. This dedicated news hub provides investors and industry observers with essential updates on clinical developments, regulatory milestones, and strategic partnerships.
Access timely reports on Synlogic's synthetic biotics platform progress, including trial results for phenylketonuria (PKU) therapies and microbiome research breakthroughs. Our curated collection features earnings announcements, patent filings, and scientific collaborations that shape the company's trajectory in biopharmaceutical innovation.
Key updates include FDA designations, partnership agreements with leading research institutions, and advancements in oral therapeutic delivery systems. Bookmark this page for streamlined access to verified information about Synlogic's novel approach to metabolic disease treatment.
Synlogic, Inc. (SYBX) announced its fourth-quarter and full-year 2022 financial results, highlighting significant advancements in its pipeline for treating phenylketonuria (PKU) and homocystinuria (HCU). The company is on track to initiate its pivotal Phase 3 trial for SYNB1934 in PKU by mid-2023. Additionally, it received Rare Pediatric Disease Designation for SYNB1934 and SYNB1353. Financially, Synlogic reported revenues of $1.2 million for 2022, a decrease from $1.8 million in 2021, with a net loss of $66.1 million, or $0.92 per share. The company has $77.6 million in cash to support operations through the second half of 2024.
